Leerink Partnrs Analysts Cut Earnings Estimates for BSX

Key Points

• Leerink Partners has revised its Q3 2025 earnings per share (EPS) estimate for Boston Scientific down to $0.71, slightly lower than the previous estimate of $0.72.
• The consensus estimate for Boston Scientific's full-year earnings is $2.85 per share, with forecasts outlining a steady growth trajectory through FY2029.
• Boston Scientific shares traded down 0.1% to around $106.07 with a market cap of $156.92 billion and have seen significant insider selling recently.

Boston Scientific Corporation (NYSE:BSX - Free Report) - Stock analysts at Leerink Partnrs cut their Q3 2025 earnings per share estimates for Boston Scientific in a report released on Wednesday, July 23rd. Leerink Partnrs analyst M. Kratky now forecasts that the medical equipment provider will post earnings of $0.71 per share for the quarter, down from their prior estimate of $0.72. Leerink Partnrs currently has a "Strong-Buy" rating on the stock. The consensus estimate for Boston Scientific's current full-year earnings is $2.85 per share. Leerink Partnrs also issued estimates for Boston Scientific's Q4 2025 earnings at $0.77 EPS, FY2025 earnings at $2.98 EPS, Q1 2026 earnings at $0.76 EPS, Q2 2026 earnings at $0.84 EPS, Q3 2026 earnings at $0.86 EPS, Q4 2026 earnings at $0.93 EPS, FY2026 earnings at $3.40 EPS, FY2027 earnings at $4.06 EPS, FY2028 earnings at $4.51 EPS and FY2029 earnings at $5.01 EPS.

BSX has been the subject of several other reports. Wall Street Zen raised Boston Scientific from a "hold" rating to a "buy" rating in a research note on Tuesday, April 29th. Jefferies Financial Group reissued a "hold" rating on shares of Boston Scientific in a report on Monday, July 21st. Royal Bank Of Canada reaffirmed an "outperform" rating on shares of Boston Scientific in a research note on Thursday. Raymond James Financial upped their price objective on Boston Scientific from $121.00 to $124.00 and gave the company a "strong-buy" rating in a research note on Thursday. Finally, Needham & Company LLC reiterated a "buy" rating and set a $115.00 target price on shares of Boston Scientific in a research report on Wednesday, May 28th. Two equities research analysts have rated the stock with a hold rating, twenty-two have given a buy rating and three have assigned a strong buy rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Buy" and an average target price of $117.50.

Boston Scientific Trading Up 0.0%

Shares of NYSE BSX traded up $0.05 during trading on Friday, reaching $106.19. The stock had a trading volume of 2,320,621 shares, compared to its average volume of 7,707,352. Boston Scientific has a fifty-two week low of $71.88 and a fifty-two week high of $108.94. The company has a debt-to-equity ratio of 0.47, a quick ratio of 0.88 and a current ratio of 1.45. The business's 50-day moving average price is $103.58 and its 200-day moving average price is $101.59. The company has a market cap of $157.10 billion, a P/E ratio of 63.21, a PEG ratio of 2.55 and a beta of 0.68.

Boston Scientific (NYSE:BSX - Get Free Report) last issued its quarterly earnings data on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share for the quarter, beating analysts' consensus estimates of $0.72 by $0.03. Boston Scientific had a return on equity of 19.39% and a net margin of 13.55%. The business had revenue of $5.06 billion during the quarter, compared to analysts' expectations of $4.89 billion. During the same period in the previous year, the firm posted $0.62 earnings per share. The company's revenue was up 22.8% on a year-over-year basis.

Insiders Place Their Bets

In other news, EVP Joseph Michael Fitzgerald sold 50,000 shares of the firm's stock in a transaction on Tuesday, July 1st. The stock was sold at an average price of $106.97, for a total transaction of $5,348,500.00. Following the sale, the executive vice president owned 178,342 shares in the company, valued at $19,077,243.74. This trade represents a 21.90% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Arthur C. Butcher sold 17,314 shares of the firm's stock in a transaction on Thursday, May 1st. The stock was sold at an average price of $102.06, for a total value of $1,767,066.84. Following the sale, the executive vice president owned 22,235 shares in the company, valued at $2,269,304.10. This trade represents a 43.78% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 457,144 shares of company stock worth $47,296,288 over the last ninety days. Company insiders own 0.50% of the company's stock.

Institutional Investors Weigh In On Boston Scientific

Hedge funds have recently made changes to their positions in the business. Colonial Trust Co SC raised its position in shares of Boston Scientific by 1,625.0% in the 4th quarter. Colonial Trust Co SC now owns 276 shares of the medical equipment provider's stock worth $25,000 after buying an additional 260 shares during the period. Investment Management Corp VA ADV purchased a new position in shares of Boston Scientific in the 4th quarter worth $25,000. Sunbeam Capital Management LLC purchased a new position in shares of Boston Scientific in the 4th quarter worth $26,000. 1248 Management LLC purchased a new position in shares of Boston Scientific in the 1st quarter worth $26,000. Finally, Y.D. More Investments Ltd purchased a new position in shares of Boston Scientific in the 1st quarter worth $27,000. Institutional investors and hedge funds own 89.07% of the company's stock.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.